Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7963080 | 1.00 | HDAC3 (0.34) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL1274513 | 0.89 | CES1 (0.36) | ALDH1A1CES2CES1LMNAMAPK1 | |
| SCHEMBL20551748 | 0.84 | ALDH1A1 (0.33) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL20551746 | 0.84 | ALDH1A1 (0.33) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL600808 | 0.83 | ALDH1A1 (0.40) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL600809 | 0.83 | ALDH1A1 (0.40) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL1275353 | 0.81 | HCAR2 (0.35) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL6034823 | 0.78 | — | — | |
| SCHEMBL11170023 | 0.77 | ALDH1A1 (0.51) | HDAC3HDAC1HDAC2HDAC8ALDH1A1 | |
| SCHEMBL11170026 | 0.77 | ALDH1A1 (0.51) | HDAC3HDAC1HDAC2HDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20150284395-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2015-10-08 | — | — | US | disclosed |
| US-6218397-B1 | FOR THERAPY OF STRESS-RELATED ILLNESSES, SUCH AS STRESS-INDUCED DEPRESSION, ANXIETY, AND HEADACHE; ABDOMINAL BOWEL SYNDROME; INFLAMMATORY DISEASES; IMMUNE SUPPRESSION; ALZHEIMER'S DISEASE; GASTRONINTESTINAL DISEASES | PFIZER INC | 2001-04-17 | — | — | US | disclosed |
| EP-0674642-B1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0674642-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013677-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392389-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | HDAC3 679/4885HDAC1 457/4885HDAC2 948/4885 |
| US-20150284395-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | HDAC3 679/4885HDAC1 457/4885HDAC2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.